[Breast Cancer: Targets and Therapy] This research examines possible core biomarkers for triple-negative breast cancer.
A review of HER2-positive breast cancer, including etiology, diagnosis, and treatments.
Study results presented at the 2018 Gastrointestinal Cancers Symposium demonstrated the sensitivity and specificity of the CMx biomimetic platform, a novel approach to detecting CRC and precancerous lesions that could improve screening rates.
Protein produced by chronically infected cells in persons with HPV16 infection serves as a biomarker for risk of cancer of the oropharynx.
Prospective pilot study demonstrates accuracy of circulating tumor cells as a biomarker indicating lung cancer recurrence.
Novel diagnostic test determines whether suspicious lung lesions or nodules are malignant disease from a sample obtained via nasal swab.
A protocol of testing of CA125 levels quarterly with subsequent transvaginal ultrasound examination increased detection of early-stage ovarian cancer in women at high-risk for the disease.
Research presented at SABCS 2016 identified biomarkers predictive of response to trastuzumab-containing therapies in patients with HER2-positive breast cancer.
Expression of this hormone receptor may indicate a less aggressive subtype of triple-negative breast cancer and better prognosis for patients with the disease.
Presence of certain microRNAs (miRNAs) is predictive of response to TKIs and prognosis for patients with metastatic renal cell carcinoma (mRCC).
